# A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration

> **NCT00950638** · PHASE1 · COMPLETED · sponsor: **Ophthotech Corporation** · enrollment: 47 (actual)

## Conditions studied

- Dry Age-Related Macular Degeneration

## Interventions

- **DRUG:** Avacincaptad Pegol

## Key facts

- **NCT ID:** NCT00950638
- **Lead sponsor:** Ophthotech Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07-16
- **Primary completion:** 2011-03-24
- **Final completion:** 2011-03-24
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2025-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00950638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00950638, "A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00950638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*